Lab Monkey Prices Surge 570% Amid Shortage
Drug developers and contract researchers that rely on primates face higher costs and longer sourcing timelines.
Updated on Nov. 2, 2026 in Healthcare
Live Poll
Should the US keep using monkeys in drug safety testing?
Prices for lab-bred monkeys used in US biomedical research have risen sharply amid a supply shortage tied to China's export restrictions. Operators in research-dependent healthcare supply chains face higher per-animal costs and longer sourcing timelines.
Why it matters
China's export restrictions during the COVID-19 pandemic cut off a key supplier, forcing American labs to compete for limited domestic stock. The shortage has pushed prices up roughly 570 percent, altering the cost base for drug developers and testing contractors that depend on non-human primates.
US lab monkey prices rose about 570 percent, from $3,000 to $20,000, and Charles River Laboratories' monkey price climbed from around $2,500 in 2019 to $22,000 in 2022. A safety study for a lab-produced monoclonal antibody can involve about 144 non-human primates at $50,000 each.
The players
Humane Medicine
A startup founded in 2023 that plans to breed macaques domestically for laboratory research, having raised $28 million.
Joe Lonsdale
Co-founder of Palantir and an investor backing Humane Medicine's domestic primate breeding effort.
Charles River Laboratories
A major contract research and lab animal supplier whose monkey prices rose sharply between 2019 and 2022.
The details
Humane Medicine, a startup founded in 2023 and backed by Palantir co-founder Joe Lonsdale, plans to breed macaques domestically to address the shortage, with a facility planned in Bainbridge, Georgia that could eventually house up to 30,000 long-tailed macaques. Female macaques reach sexual maturity around age four and typically give birth to one offspring per year, which limits how quickly breeding capacity can grow. The startup has raised $28 million since its founding.
Timeline
2019: Lab monkey prices were about $3,000 per animal.
2020: COVID-19 pandemic prompted China to impose export restrictions on research monkeys.
2022: Charles River monkey prices reached $22,000.
2023: Humane Medicine was founded.
Market Landscape
The shortage traces to China's 2020 export restrictions on research monkeys, which left US labs dependent on a constrained domestic supply. Humane Medicine's planned Georgia facility represents an attempt to build domestic breeding capacity that would reduce that import dependence over time.
Healthcare firms and contract researchers that depend on non-human primates should model higher per-animal costs and longer sourcing lead times in their budgets. Procurement teams should evaluate alternative testing methods and domestic supplier options as the market adjusts.
The takeaway
Operators in research-dependent healthcare should treat primate sourcing as a volatile input cost rather than a stable one. Track the progress of domestic breeding facilities such as Humane Medicine's Georgia project, since its output will determine whether prices stabilize.
Further reading
For broader context on the supply pressures shaping medical research, see our Healthcare coverage.
Source note: This article includes information reported by Ajel.
Live Poll
Should the US keep using monkeys in drug safety testing?
